Literature DB >> 8378510

Challenges in medication clinical trials.

M V Rudorfer1.   

Abstract

The keystone of pharmacological therapy is the medication clinical trial. Beyond the straightforward administration of an adequate amount of medication for a sufficient duration of time, attention to a variety of methodologic issues is necessary to ensure a successful study. These include diagnostic and severity criteria for entry into the trial and a host of potentially confounding biological and psychosocial factors. Adequacy of treatment must be insured, aided by continued refinement of plasma drug concentration monitoring and understanding of the role of active metabolites. Outcome measures must be valid and reliable. These principles are being applied to the still-new field of child and adolescent psychopharmacology. Results thus far have indicated the importance of placebo control in young populations. The equivocal efficacy demonstrated to date for pharmacotherapy in controlled antidepressant trials in children and adolescents has limited understanding of dose (or plasma level)/response relationships which could serve to optimize further studies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8378510

Source DB:  PubMed          Journal:  Psychopharmacol Bull        ISSN: 0048-5764


  4 in total

1.  Challenges associated with controlled psychopharmacological research trials in adolescents with eating disorders.

Authors:  Mark L Norris; Wendy Spettigue; Annick Buchholz; Katherine A Henderson
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2007-11

Review 2.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 3.  Generalised anxiety disorder: treatment options.

Authors:  John J Sramek; Victoria Zarotsky; Neal R Cutler
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 4.  Metabolism of tricyclic antidepressants.

Authors:  M V Rudorfer; W Z Potter
Journal:  Cell Mol Neurobiol       Date:  1999-06       Impact factor: 5.046

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.